The present disclosure provides the use of fratricide-resistant chimeric antigen receptor T (CAR-T) cells targeting antigens expressed by T cell malignancies.
Loading patent
Gene editing of CAR-T cells for the treatment of T cell malignancies with …
US12564648B2 · 03/03/2026
The present disclosure provides the use of fratricide-resistant chimeric antigen receptor T (CAR-T) cells targeting antigens expressed by T cell malignancies.
Full text
1 sectionsNo articles yet — metadata is still available from the registry.
Comments
0 replies · cite patents with ^
Join the discussion
Continue with GoogleNo comments yet.